<DOC>
	<DOCNO>NCT00462462</DOCNO>
	<brief_summary>Absolute ethanol use `` off-label '' unmodified formulation ( solution ) Congenital Venous Malformations ( CVM ) . Despite effectiveness , absolute ethanol appear difficult handle high diffusion capacity outside CVM blood circulation . A less diffusible ethanol-based product ( ethanol gel ) develop order minimize systemic local diffusion capacity ethanol . Therefore , pharmacokinetic parameter clinical paraclinical outcome ethanol gel 96 % absolute ethanol need carry . FDA Office Orphan Products Development ( FDA OOPD ) : Funding source .</brief_summary>
	<brief_title>Systemic Local Diffusion Ethanol After Administration Ethanol 96 % Formulated Gel Ethanol 98 % Solution Percutaneous Route , Patients With Congenital Venous Malformations : Pharmacokinetic , Pharmacodynamic Clinical Study .</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Patients sex , least 12 year age , For woman childbearing potential , negative pregnancy test baseline , Patients one clinically radiologically ( MRI ) document lesion diagnose CVM ( pure predominant ) , Patients embolosclerotherapy percutaneous route indicate first line therapy test lesion , previous treatment ( i.e . surgery , embolosclerotherapy , laser ) unsuccessful insufficient , Patients CVM lesional size least 12 cm3 ( maximum craniocaudal dimension X mean dimension 3 transverse equispaced measurement X mean dimension 3 deepness equispaced measurement dimension ) MRI , Patients focal multifocal CVM lesion , i.e . one several wellinterconnecting venous space welldefined margin , Patients parent able follow study instruction attend study visit , Written inform consent patient parent . Exclusion criterion : Patients 12 year age , Pregnant woman , nurse mother woman childbearing potential reliable contraception 2 month , Women childbearing potential positive pregnancy test baseline , Patients CVM non venous predominance , Patients CVM reachable percutaneous route , Patients extensive superficial skin CVM ( i.e . high risk skin necrosis ) , Patients test lesion adjacent major nerve ( e.g . facial nerve parotid region , intramuscular region adjacent major nerve ) , Patients facial CVM bone involvement , Patients small CVM lesion ( &lt; 12 cm3 MRI ) , Patients require 1 ml/Kg body weight ( b.w . ) USA 0.5 ml/Kg b.w . France , 30 mL absolute ethanol infuse , Patients know allergy one component test product , Patients suspect allergy iodinate.ed product , Patients abnormal clot parameter ( platelet , partial thromboplastin , prothrombin time ) , Patients active inflammatory episode test lesion ( i.e . acute subacute swell test lesion ) , Patients complex malformation ( e.g . KlippelTrenaunay syndrome , Blue Rubber Bled Nevus syndrome , Mucocutaneous familial venous malformation , Mafucci 's syndrome ) , Patients surgery , laser therapy embolosclerotherapy test lesion perform within last 12 week prior study entry , Asthmatic patient require daily medication , Patients non treat non stabilized cardiac disease , Patients suspect rightleft shunt , Patients intercurrent condition concomitant treatment may interfere good conduct evaluation parameter study , Patients participate study within 12 week prior study entry , Patients parent able willing follow study instruction , Patients parent refuse give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>